Search | Clinical Trials Finder

Conditions: Depressive Symptoms
Interventions: Parent-Specific Depression Education and Motivation, General Depression Education-Motivation; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pregnancy
Interventions: pharmacist nicotine cessation counseling using SCRIPT protocol; Behavioral
Lead sponsor: Providence Medical Research Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Bladder Cancer
Interventions: Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery), Geriatric Service/ Discharge Planning, Questionnaires; Other
Lead sponsor: University of Chicago; Other
Eligibility: 65 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions: Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab; Drug · Biological
Lead sponsor: Intima Bioscience, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Duarte, California • Minneapolis, Minnesota

Conditions: Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee

Conditions: Chronic Pain, Back Pain
Interventions: Yoga; Behavioral
Lead sponsor: Robert Saper; Other
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Enasidenib, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Buffalo, New York • East Hills, New York

Conditions: HIV-1-infection
Interventions: GS-1219, BVY, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Bacterial Infections
Interventions: 11C-Trimethoprim; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions: Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery; Drug · Radiation · Other + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 154
States / cities: Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more

Conditions: Pilonidal Disease
Interventions: Laser hair removal; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 13 Years to 35 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Aging, Alzheimer Disease, Age-related Cognitive Decline
Interventions: Brain training, Paced breathing; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 50 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions: Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more

Conditions: Adenovirus Infection, EBV Infection
Interventions: Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more

Conditions: Pediatric Cardiac Surgery
Interventions: Methadone based ERAS, Non-methadone based group; Drug
Lead sponsor: Senthil Sadhasivam; Other
Eligibility: 3 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Oakland, California • Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Little Rock, Arkansas • Oakland, California • Orange, California + 8 more

Conditions: Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more

Conditions: Cancer
Interventions: Educational Intervention, Follow-Up Care, Psychosocial Assessment and Care, Questionnaire Administration; Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: ibrutinib, Correlative laboratory samples, quality of life assessment; Drug · Other
Lead sponsor: Kami Maddocks, MD; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Radius Fractures
Interventions: StabilAir Wrist Brace, Placement of sugar tong splint or plaster cast; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Tobacco Use Disorder, Substance Use Disorder (SUD)
Interventions: Contingency Management (CM), Treatment as Usual (TAU); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Small Cell Lung Cancer, Lung Cancer Stage III
Interventions: Thoracic RT and Durvalumab, Consolidative Durvalumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatitis C, Chronic
Interventions: Previous treatment in DEB025 study; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: San Diego, California • Ventura, California • Honolulu, Hawaii + 4 more

Search by objective public record fields.

Parent Specific Depression Education and Motivation

Evaluation of the Effectiveness of Pharmacists in Implementing the SCRIPT Protocol

Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy

CISH Inactivated TILs in the Treatment of NSCLC

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

Yoga for Chronic Low Back Pain in the Cleveland Clinic Employee Health Plan

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Study of GS-1219 in Participants With HIV-1

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Laser Hair Removal for Treatment of Pilonidal Disease

Heart Rate and Breathing Effects on Attention and Memory

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

Evaluation of Analgesia for Cardiac Elective Surgery in Children

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace

Contingency Management for Veteran Smokers Undergoing Major Elective Surgery

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study